- Home
- EEA vs NRXP Comparison
EEA vs NRXP Comparison
Compare EEA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EEA | NRXP |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | Germany | |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 62.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EEA | NRXP |
|---|---|---|
| Price | $10.90 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 9.2K | ★ 569.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.45 | $1.58 |
| 52 Week High | $9.26 | $3.84 |
Technical Indicators
Market Signals| Indicator | EEA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 54.33 | 40.74 |
| Support Level | $10.88 | $1.70 |
| Resistance Level | $11.03 | $2.00 |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 37.41 | 27.78 |
Price Performance
Historical ComparisonAbout EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.